F9
ENSG00000101981
Target class
Enzyme
Chromosome
X
Approved drugs
9
Clinical candidates (approved and in development)
12
- Approved drugs
- 9
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 12
- Chemical probe available
- No
- Other names
- FIX
- Target name
- F9
- Gene name
- Coagulation factor IX
- Gene symbol
- F9
- Protein name
- Coagulation factor IX (EC 3.4.21.22) (Christmas factor) (Plasma thromboplastin component) (PTC) [Cleaved into: Coagulation factor IXa light chain; Coagulation factor IXa heavy chain]
- Gene biotype
- Protein coding
- Gene family
- Gla domain containing
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 235.26
- Tissue specificity (Gini)
- 0.981
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:2158
- Protein interaction confidence
- 0.855826
- Protein interaction partners
- 23
- R-HSA-159740
- R-HSA-159763
- R-HSA-159782
- R-HSA-9629569
- R-HSA-9672383
- R-HSA-9672396
- R-HSA-9673202
- R-HSA-9673218
- R-HSA-9673221
- R-HSA-9673240
- R-HSA-9769735
- R-HSA-9769739
- R-HSA-9769743
- R-HSA-9935598
- End position
- 139563459
- Start position
- 139530739
- Chromosome
- X
- Strand
- Forward
- Secreted .
- PubMed 19846852
- PubMed 2592373
- PubMed 3857619
- PubMed 8295821
- PubMed 9169594
- Tissue specificity (tau)
- 0.99999
- Expression inequality (Gini)
- 0.981447
Expression in transcripts per million
- Liver
- 235.26
- Testis
- 0.07
- Cervix - Ectocervix
- 0.04
- Spleen
- 0.01
- Cervix - Endocervix
- 0.01
Expression in transcripts per million
- Liver235.26
- Testis0.07
- Cervix - Ectocervix0.04
- Spleen0.01
- Cervix - Endocervix0.01
- Kidney - Medulla0
- Brain - Hypothalamus0
- Muscle - Skeletal0
- Skin - Sun Exposed (Lower leg)0
- Fallopian Tube0
- Heart - Left Ventricle0
- Prostate0
- Artery - Aorta0
- Colon - Sigmoid0
- Adrenal Gland0
- Brain - Caudate (basal ganglia)0
- Artery - Coronary0
- Small Intestine - Terminal Ileum0
- Brain - Nucleus accumbens (basal ganglia)0
- Brain - Substantia nigra0
- Heart - Atrial Appendage0
- Adipose - Subcutaneous0
- Cells - Cultured fibroblasts0
- Whole Blood0
- Brain - Anterior cingulate cortex (BA24)0
And 29 more, listed on the interactive page.
- GO:0006508
- GO:0007596
- GO:0031638
- GO:0005576
- GO:0005788
- GO:0005796
- GO:0005886
- GO:0031012
- GO:0070062
- GO:0004175
- GO:0004252
- GO:0005509
- GO:0005515
- GO:0046872
Related records
Trials (1,260)
- - 4th Visit at 17 Years of Cohort STANISLAS - Stanislas Ancillary Study ESCIF
- "Circulating Fetal DNA, Pregnancy And Immune Diseases"
- "Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"
- 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol
- 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2
- A 3D Hydrogel Model to Assess Endothelial Cell-macrophage Interactions in Simulated Microgravity (OR-DRPD-SRI2019)
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy
- A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
- A DERMO-EPIDERMAL AUTOLOGOUS SKIN SUBSTITUTE FOR FURTHER THERAPEUTIC USE
- A European Network for the Investigation of Gender Incongruence
- A Gene Therapy Study for Hemophilia B
- A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)
- A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- A Prospective, Mono-center, Interventional Study Evaluating the Effect of One Year Initial Care by Hygieno-dietary Advices With or Without Phlebotomy on Glycemia After at Least 5 Years in Patients With Dysmetabolic Iron Overload Syndrome
- A Randomized Control Trial to Evaluate the Efficacy of Autologous Blood Injection Versus Local Corticosteroid Injection for Treatment of Lateral Epicondylitis
- A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study
- A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
Drugs (12)
- Albutrepenonacog alfa Coagulation factor IX exogenous protein
- Coagulation factor IX human Coagulation factor IX exogenous protein
- Coagulation factor IX recombinant human Coagulation factor IX exogenous protein
- Eftrenonacog alfa Coagulation factor IX exogenous protein
- Emicizumab Coagulation factor IX and X other
- Etranacogene dezaparvovec Coagulation factor IX exogenous protein
- Fidanacogene elaparvovec Coagulation factor IX exogenous gene
- Nonacog beta pegol Coagulation factor IX exogenous protein
- Pegnivacogin Coagulation factor IX inhibitor
- Prothrombin complex concentrate Coagulation factor IX exogenous protein
- Trenonacog alfa Coagulation factor IX exogenous protein
- Valoctocogene roxaparvovec Coagulation factor IX exogenous protein